Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the 14 safe stocks to buy now for a starter stock portfolio.

Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry

On February 23, Piper Sandler boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $75 from $66 while keeping an Overweight rating on the company’s shares. The firm outlined two avenues for the pharma giant’s comeback to top-line growth after the loss of exclusivity for Eliquis in the US in 2028.

The first option is the efficacy of milvexian in the LIBREXIA AF study for atrial fibrillation. At the same time, the second track comprises pipeline progress, including label upgrades for Cobenfy, admilparant, CELMoD treatments such as iberdomide and mezigdomide, and ryz101.

Meanwhile, RBC Capital launched coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. According to the firm, Bristol-Myers has the most extensive Phase 3 pipeline among large-cap pharma companies.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious diseases, including cancer, blood disorders, immune conditions, cardiovascular disease, and neurological disorders.

While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.